MLchartDataset catalogue

anti-VEGF/TGF-beta bispecific antibody fusion protein ZGGS18

Term · Oncology and biomedicine · MLC-T-ONC-011180

A bifunctional antibody fusion protein targeting both vascular endothelial growth factor (VEGF) and the pro-inflammatory cytokine human transforming growth factor beta (TGF-beta; TGFb), with potential antineoplastic activity. Upon administration, anti-VEGF/TGF-beta bispecific antibody fusion protein ZGGS18 targets, binds to and neutralizes both VEGF and TGF-beta. This prevents VEGF- and TGF-beta-mediated signaling and abrogates VEGF/VEGFR-induced angiogenesis and TGF-beta-mediated induction of VEGF, which further inhibits angiogenesis. It also inhibits TGF-beta-mediated immunosuppression, thereby enhancing anti-tumor immunity in the tumor microenvironment (TME) and promoting a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. VEGF is upregulated in a variety of cancer cell types and plays a crucial role in angiogenesis. TGF-beta, dysregulated in many types of cancer, plays a key role in immunosuppression in the TME, enhances tumor cell proliferation, and promotes cancer progression.

Table 1. Record
IdentifierMLC-T-ONC-011180
FieldOncology and biomedicine
Synonymsanti-VEGF/TGF-beta bifunctional antibody fusion protein ZGGS18; anti-VEGF/anti-TGF-beta bispecific antibody fusion protein ZGGS18; VEGF x TGF-beta bispecific antibody fusion protein ZGGS18
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-011180",
  "term": "anti-VEGF/TGF-beta bispecific antibody fusion protein ZGGS18",
  "field": "Oncology and biomedicine",
  "definition": "A bifunctional antibody fusion protein targeting both vascular endothelial growth factor (VEGF) and the pro-inflammatory cytokine human transforming growth factor beta (TGF-beta; TGFb), with potential antineoplastic activity. Upon administration, anti-VEGF/TGF-beta bispecific antibody fusion protein ZGGS18 targets, binds to and neutralizes both VEGF and TGF-beta. This prevents VEGF- and TGF-beta-mediated signaling and abrogates VEGF/VEGFR-induced angiogenesis and TGF-beta-mediated induction of VEGF, which further inhibits angiogenesis. It also inhibits TGF-beta-mediated immunosuppression, thereby enhancing anti-tumor immunity in the tumor microenvironment (TME) and promoting a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. VEGF is upregulated in a variety of cancer cell types and plays a crucial role in angiogenesis. TGF-beta, dysregulated in many types of cancer, plays a key role in immunosuppression in the TME, enhances tumor cell proliferation, and promotes cancer progression.",
  "synonyms": [
    "anti-VEGF/TGF-beta bifunctional antibody fusion protein ZGGS18",
    "anti-VEGF/anti-TGF-beta bispecific antibody fusion protein ZGGS18",
    "VEGF x TGF-beta bispecific antibody fusion protein ZGGS18"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-vegf-tgf-beta-bispecific-antibody-fusion-protein-zggs18/"
}

Record 2,332 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.